RESUMEN
PURPOSE: To examine the current evidence on breast lymphedema (BL) diagnosis and treatment after breast-conserving surgery, identify gaps in the literature, and propose future research directions. METHODS: A comprehensive literature review was conducted using Ovid, PubMed, and Cochrane, including studies published between 2000 and 2023. References were reviewed manually for eligible studies. Inclusion criteria were as follows: patients who underwent breast conserving treatment (surgery ± radiation) for breast cancer, goals of the paper included analyzing or reviewing BL measurement with ultrasound or tissue dielectric constant, or BL treatment. Twenty-seven manuscripts were included in the review. RESULTS: There is variation in incidence, time course, and risk factors for BL. Risk factors for BL included breast size, primary and axillary surgery extent, radiation, and chemotherapy but require further investigation. Diagnostic methods for BL currently rely on patient report and lack standardized criteria. Tissue dielectric constant (TDC) and ultrasound (US) emerged as promising ambulatory BL assessment tools; however, diagnostic thresholds and validation studies with ICG lymphography are needed to establish clinical utility. The evidence base for treatment of BL is weak, lacking high-quality studies. CONCLUSION: The natural history of BL is not well defined. TDC and US show promise as ambulatory assessment tools for BL; however, further validation with lymphatic imaging is required. BL treatment is not established in the literature. Longitudinal, prospective studies including pre-radiation measurements and validating with lymphatic imaging are required. These data will inform screening, diagnostic criteria, and evidence-based treatment parameters for patients with BL after breast-conserving surgery and radiation.
Asunto(s)
Linfedema del Cáncer de Mama , Neoplasias de la Mama , Linfedema , Humanos , Femenino , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/complicaciones , Estudios Prospectivos , Linfedema/diagnóstico , Linfedema/epidemiología , Linfedema/etiología , Mastectomía Segmentaria/efectos adversos , Axila , Linfedema del Cáncer de Mama/diagnóstico , Linfedema del Cáncer de Mama/epidemiología , Linfedema del Cáncer de Mama/etiologíaRESUMEN
PURPOSE: We aimed to evaluate whether neoadjuvant chemotherapy (NAC) could be a risk factor for breast cancer-related lymphedema (BCRL) associated with axillary lymph node dissection (ALND). PATIENTS AND METHODS: A total of 596 patients with cT0-4N0-3M0 breast cancer who underwent ALND and chemotherapy were retrospectively analyzed between March 2012 and March 2022. NAC was administered in 188 patients (31.5%), while up-front surgery in 408 (68.5%). Univariate and multivariable Cox regression analyses were performed to determine whether NAC was an independent risk factor for BCRL. With propensity score matching (PSM), the NAC group and up-front surgery group were matched 1:1 by age, body mass index (BMI), molecular subtypes, type of breast surgery, and the number of positive lymph nodes. Kaplan-Meier survival analyses were performed for BCRL between groups before and after PSM. Subgroup analyses were conducted to explore whether NAC differed for BCRL occurrence in people with different characteristics. RESULTS: At a median follow-up of 36.3 months, 130 patients (21.8%) experienced BCRL [NAC, 50/188 (26.60%) vs. up-front surgery, 80/408 (19.61%); P = 0.030]. Multivariable analysis identified that NAC [hazard ratio, 1.503; 95% CI (1.03, 2.19); P = 0.033] was an independent risk factor for BCRL. In addition, the hormone receptor-negative/human epidermal growth factor receptor 2-negative (HR-/HER2-) subtype, breast-conserving surgery (BCS), and increased positive lymph nodes significantly increased BCRL risk. After PSM, NAC remained a risk factor for BCRL [hazard ratio, 1.896; 95% CI (1.18, 3.04); P = 0.007]. Subgroup analyses showed that NAC had a consistent BCRL risk in most clinical subgroups. CONCLUSION: NAC receipt has a statistically significant increase in BCRL risk in patients with ALND. These patients should be closely monitored and may benefit from early BCRL intervention.
Asunto(s)
Linfedema del Cáncer de Mama , Neoplasias de la Mama , Linfedema , Humanos , Femenino , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Terapia Neoadyuvante/efectos adversos , Estudios Retrospectivos , Escisión del Ganglio Linfático/efectos adversos , Linfedema del Cáncer de Mama/epidemiología , Linfedema del Cáncer de Mama/etiología , Linfedema del Cáncer de Mama/patología , Axila/patología , Biopsia del Ganglio Linfático Centinela/efectos adversos , Ganglios Linfáticos/patología , Linfedema/epidemiología , Linfedema/etiología , Linfedema/patologíaRESUMEN
PURPOSE: Lower extremity lymphedema (LEL), which causes ankle, leg, and feet swelling, poses a significant challenge for endometrial cancer survivors, impacting physical functioning and psychological well-being. Inconsistent LEL diagnostic methods result in wide-ranging LEL incidence estimates. METHODS: We calculated the cumulative incidence of LEL based on survivor-reported Gynecologic Cancer Lymphedema Questionnaire (GCLQ) responses in addition to survivor- and nurse-reported leg circumference measurements among a pilot sample of 50 endometrial cancer survivors (27 White, 23 Black) enrolled in the ongoing population-based Carolina Endometrial Cancer Study. RESULTS: Self-leg circumference measurements were perceived to be difficult and were completed by only 17 survivors. Diagnostic accuracy testing measures (sensitivity, specificity, positive and negative predictive value) compared the standard nurse-measured ≥ 10% difference in leg circumference measurements to GCLQ responses. At a mean of ~11 months post-diagnosis, 54% of survivors met established criteria for LEL based on ≥ 4 GCLQ cutpoint while 24% had LEL based on nurse-measurement. Percent agreement, sensitivity, and specificity approximated 60% at a threshold of ≥ 5 GCLQ symptoms. However, Cohen's kappa, a measure of reliability that corrects for agreement by chance, was highest at ≥ 4 GCLQ symptoms (κ = 0.27). CONCLUSION: Our findings emphasize the need for high quality measurements of LEL that are feasible for epidemiologic study designs among endometrial cancer survivors. Future studies should use patient-reported survey measures to assess lymphedema burden and quality of life outcomes among endometrial cancer survivors.
Asunto(s)
Supervivientes de Cáncer , Neoplasias Endometriales , Linfedema , Humanos , Femenino , Neoplasias Endometriales/complicaciones , Neoplasias Endometriales/psicología , Supervivientes de Cáncer/psicología , Persona de Mediana Edad , Linfedema/etiología , Linfedema/epidemiología , Linfedema/diagnóstico , Linfedema/psicología , Anciano , Encuestas y Cuestionarios , Autoevaluación (Psicología) , Adulto , IncidenciaRESUMEN
BACKGROUND: Patients with lymphedema and lipedema share physical exam findings that may lead to misdiagnosis. Poor mobility is common in patients with obesity and patients with lymphedema and lipedema. This may constitute a risk factor for venous thromboembolism (VTE). Our objective was to evaluate the association of VTE in obese patients with lymphedema and lipedema. METHODS: The National Inpatient Sample (NIS) was searched from 2016 to 2020 to identify hospital admissions of obese female patients with lymphedema and lipedema. Patients were analyzed in the context of presence or absence of VTE while adjusting for complex cluster sampling techniques. Predictors of VTE were accessed by multivariable regression. RESULTS: Lymphedema was identified in 189,985 patients and lipedema in 50,645 patients. VTE was observed in 3.12% (n = 374,210) of patients with obesity. In patients with obesity, VTE was more common in patients with lymphedema than without (2.6% vs 1.6%; p < 0.01). Similarly, VTE was more common in patients with lipedema than without (0.6% vs 0.4%; p < 0.01). After multivariable logistic regression, VTE events in obese patients with lymphedema were higher versus without (OR 1.6; CI 1.08-2.43; p = 0.02). Similarly, VTE events were more common in obese patients with lipedema versus obese patients without lipedema (OR 1.20; CI 1.03-1.41; p = 0.02). CONCLUSIONS: In this hypothesis-generating study, lymphedema and lipedema show a positive association with VTE after adjusting for baseline patient characteristics such as obesity, which is a known independent risk factor for VTE. Mechanisms whereby lymphedema and lipedema are associated with VTE should be investigated.
Asunto(s)
Lipedema , Linfedema , Tromboembolia Venosa , Humanos , Femenino , Lipedema/diagnóstico , Lipedema/epidemiología , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/epidemiología , Pacientes Internos , Linfedema/diagnóstico , Linfedema/epidemiología , Factores de Riesgo , Obesidad/complicaciones , Obesidad/diagnóstico , Obesidad/epidemiologíaRESUMEN
BACKGROUND: Lymphoedema is a globally neglected health care problem and a common complication following breast cancer treatment. Lymphoedema is a well-known predisposing factor for cellulitis, but few have investigated the risk factors for cellulitis in this patient cohort on an international level. The aim of this study was to identify the frequency of cellulitis in patients with lymphoedema of the arm, including potential risk factors for cellulitis. METHODS: An international, multi-centre, cross-sectional study including patients with clinically assessed arm lymphoedema. The primary outcome was the incidence of cellulitis located to the arm with lymphoedema within the last 12 months, and its potential associated risk factors. The secondary outcome was life-time prevalence of cellulitis. Adults with clinically-assessed arm lymphoedema/chronic oedema (all causes) and able to give informed consent were included. End-of-life-patients or those judged as not in the patient's best interest were excluded. Both univariable and multivariable analysis were performed. RESULTS: A total of 2160 patients were included from Australia, Denmark, France, Ireland, Italy, Japan, Turkey and United Kingdom. Secondary lymphoedema was present in 98% of the patients; 95% of these were judged as related to cancer or its treatment. The lifetime prevalence of cellulitis was 22% and 1-year incidence 11%. Following multivariable analysis, factors associated with recent cellulitis were longer swelling duration and having poorly controlled lymphoedema. Compared to having lymphoedema less than 1 year, the risk increased with duration: 1-2 years (OR 2.15), 2-5 years (OR 2.86), 5-10 years (OR 3.15). Patients with well-controlled lymphoedema had a 46% lower risk of cellulitis (OR 0.54, 95% CI 0.39-0.73, p < 0.001). More advanced stages of lymphoedema were associated with cellulitis even after adjustment for swelling duration and control of swelling by logistic regression (stage II OR 5.44, stage III OR 9.13, p = 0.002), demonstrated in a subgroup analysis. CONCLUSION: Patients with advanced arm lymphoedema are at particular risk of developing cellulitis. Prevention of lymphoedema progression is crucial. The results lend towards a positive effect of having well-treated lymphoedema on the frequency of cellulitis.
Asunto(s)
Neoplasias de la Mama , Linfedema , Adulto , Humanos , Femenino , Celulitis (Flemón)/epidemiología , Celulitis (Flemón)/complicaciones , Estudios Transversales , Brazo , Linfedema/epidemiología , Linfedema/etiología , Edema/complicaciones , Neoplasias de la Mama/complicacionesRESUMEN
BACKGROUND: Breast cancer-related lymphedema (BCRL) is a potentially disabling and often irreversible consequence of breast cancer treatment, caused by the mechanical incompetence of the lymphatic system, resulting in reduced drainage capacity and functional overload due to an excessive volume of interstitial fluid surpassing the system's transport capacity in the arm. We wanted to determine the impact and explore the differences in independent risk factors for the occurrence of BCRL; incidence of BCRL over a five-year period at the Institute of Oncology Vojvodina in Sremska Kamenica and to answer the research question regarding the influence of the prehabilitation program on the overall incidence of BCRL during the observed five-year period. METHODS: From 2014 to 2018, a retrospective study was conducted at the Institute of Oncology of Vojvodina in Sremska Kamenica, analyzing female patients who had undergone breast cancer surgery. RESULTS: The study included 150 breast cancer patients who developed secondary lymphedema following surgery with the mean age of 59.2 ± 11.3 years. Fluctuations in hospitalization rates were observed over the five-year period, with the highest number of admissions in 2014 (24.0%) and a decline in 2018 (14.0%). The most common surgical procedure performed was left quadrantectomy (24.0%), followed by right quadrantectomy (20.0%) and left amputation (15.3%). The mean number of removed lymph nodes was 15.2 ± 6.1, with no statistically significant association between the number of removed lymph nodes and the manifestation of secondary lymphedema. The severity of secondary lymphedema varied based on patient age, with a higher incidence of moderate and severe lymphedema observed in patients aged 61 years and older. Patients who underwent radical surgery were more likely to experience severe lymphedema compared to those who had conservative surgery, although this difference was not statistically significant. CONCLUSION: In our study, the type of surgery, elapsed time since surgery, and the number of removed lymph nodes were not influencing factors for the occurrence of BCRL. However, concerning its severity, a greater number of systemic therapy modalities combined with radiotherapy were associated with a more frequent occurrence of mild and moderate BCRL. Also, the severity of BCRL varied among different age groups, with a higher incidence of moderate and severe lymphedema observed in patients aged 61 years and older. Ultimately, improving the quality of life for individuals affected by secondary lymphedema remains a crucial goal in the field of oncology.
Asunto(s)
Linfedema del Cáncer de Mama , Neoplasias de la Mama , Supervivientes de Cáncer , Linfedema , Femenino , Humanos , Persona de Mediana Edad , Anciano , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/patología , Estudios Retrospectivos , Calidad de Vida , Linfedema/epidemiología , Linfedema/etiología , Linfedema/cirugía , Factores de Riesgo , Linfedema del Cáncer de Mama/epidemiología , Linfedema del Cáncer de Mama/complicaciones , Escisión del Ganglio Linfático/efectos adversosRESUMEN
INTRODUCTION: Treatment for melanoma after a positive sentinel lymph node biopsy includes nodal observation or lymphadenectomy. Important considerations for management, however, involve balancing the risk of recurrence and the risk of lymphedema after lymphadenectomy. METHODS: From the Merative MarketScan Research Databases, adult patients were queried from 2007 to 2021. International Classification of Disease, Ninth (ICD-9) and Tenth (ICD-10) Editions, diagnosis codes and Current Procedural Terminology codes were used to identify patients with melanoma diagnoses who underwent an index melanoma excision with a positive sentinel lymph node biopsy (SLNB). Main outcomes were completion lymph node dissection (CLND) utilization after a positive SLNB, developing lymphedema with or without CLND, and nodal basin recurrence 3 months or more after index excision. Subanalyses stratified by index excision year (2007-2017 and 2018-2021) and propensity score matched were additionally conducted. Demographics and comorbidities (measured by Elixhauser index) were recorded. RESULTS: A total of 153,085,453 patients were identified. Of those, 359,298 had a diagnosis of melanoma, and 202,456 patients underwent an excision procedure. The study cohort comprised 3717 patients with a melanoma diagnosis who underwent an excision procedure and had a positive SLNB. The mean age of the study cohort was 49 years, 57% were male, 41% were geographically located in the South, and 24% had an Elixhauser index of 4+. Among the 350 patients who did not undergo CLND, 10% experienced recurrence and 22% developed lymphedema. A total of 3367 patients underwent CLND, of which 8% experienced recurrence and 20% developed lymphedema. Completion lymph node dissection did not significantly affect risk of recurrence [odds ratio (OR), 1.370, P = 0.090] or lymphedema (OR, 1.114, P = 0.438). After stratification and propensity score matching, odds of experiencing lymphedema (OR, 1.604, P = 0.058) and recurrence (OR, 1.825, P = 0.058) after CLND were not significantly affected. Rates of CLND had significantly decreased (P < 0.001) overtime, without change in recurrence rate (P = 0.063). CONCLUSIONS: Electing for nodal observation does not increase the risk of recurrence or reduce risk of lymphedema. Just as CLND does not confer survival benefit, its decreased utilization has not increased recurrence rate.
Asunto(s)
Linfedema , Melanoma , Neoplasias Cutáneas , Adulto , Humanos , Masculino , Persona de Mediana Edad , Femenino , Melanoma/patología , Neoplasias Cutáneas/patología , Escisión del Ganglio Linfático/efectos adversos , Biopsia del Ganglio Linfático Centinela/efectos adversos , Linfedema/epidemiología , Linfedema/etiología , Linfedema/cirugía , Estudios RetrospectivosRESUMEN
Lymphedema is known to affect as many as 140 to 250 million people worldwide. Approximately 99% of lymphedemas are secondary cases after lymphadenectomy, radiation, or parasite infection. There has been no accurate estimate of the lymphedema population size in South Korea. This study aimed to quantify the epidemiology of lymphedema in South Korea and analyze the clinical characteristics of patients with lymphedema using a nationwide database. This large-scale cross-sectional study included patients who received one of the following three diagnostic codes - Q82.0 (hereditary lymphedema), I97.2 (breast cancer-related lymphedema), and I89.0 (unclassified lymphedema) from the Korean Health Insurance Review and Assessment service between January 2019 and July 2022 at tertiary hospitals, general hospitals, or other hospitals. The demographics of the lymphedema population, medication use, and medical characteristics were identified. Over the last 4 years, the annual incidence of lymphedema has steadily increased and peaked in 2021 with the number 1.85 out of 1000. Of all patients, 81% were located in the upper extremity, and 10.6% had previous cancer. Most patients were diagnosed in general hospitals (53.2%), at orthopedic surgery department (41.9%). On average, lymphedema patients spent 70.17 US dollar for medication and hospitalized for 16.9 days annually after diagnosis. Commonly prescribed medications were Entelon® (Vitis vinifera seed extract) (66.9%), steroids (40.5%), non-steroidal anti-inflammatory drugs (26.5%) and diuretics (21.8%). Only 5.7% of patients received surgery and 19.2% received herbal medicine. This is the first study in South Korea to quantify demographic and medical characteristics of lymphedema patients. These results will contribute to a comprehensive understanding of lymphedema diagnosis and treatment in our nation.
Asunto(s)
Linfedema , Humanos , República de Corea/epidemiología , Estudios Transversales , Femenino , Masculino , Linfedema/epidemiología , Persona de Mediana Edad , Adulto , Anciano , Incidencia , Adolescente , Adulto JovenRESUMEN
Lymphedema is a progressive lymphatic disease that potentiates physical and psychosocial distress. Despite its impact, patients reportedly encounter lymphatic ignorance throughout the healthcare system. This cross-sectional study aims to summarize clinical characteristics and interactions of lymphedema patients within the healthcare system. Two lymphedema patient cohorts were included: The Global Registry Analysis Cohort included lymphedema patients who contributed to an international digital lymphatic registry and the Interactions Cohort included patients who initiated a questionnaire about interactions with the medical system. The global registry was used to obtain demographic and clinical characteristics from affiliated lymphedema patients. A 23-item online questionnaire on healthcare experiences and satisfaction with lymphatic healthcare was then distributed to the Interactions Cohort. Complete responses were obtained from 2474 participants. Participants were a mean age of 57.5 ± 16.1 years and 51.4% had a cancer history. Participants reported substantial delays in diagnosis and treatment. Cancer-related and non-cancer-related lymphedema patients reported similar levels of perceived physician disinterest in their lymphedema; however, non-cancer-related lymphedema patients reported more care dissatisfaction. Ultimately, patients continue to face delays in lymphedema diagnosis and treatment. We developed an evidence-based model highlighting areas of reform needed to improve lymphatic education and healthcare.
Asunto(s)
Linfedema , Humanos , Linfedema/epidemiología , Linfedema/psicología , Femenino , Estudios Transversales , Persona de Mediana Edad , Masculino , Anciano , Encuestas y Cuestionarios , Adulto , Atención a la Salud , Satisfacción del Paciente , Sistema de Registros , Neoplasias/epidemiología , Neoplasias/psicologíaRESUMEN
OBJECTIVES: To determine the demographics, outcomes, and healthcare utilization of patients with chronic venous insufficiency-associated lymphedema (CVI-LED) and the prevalence of lymphedema-specific therapy use after venous intervention. METHODS: The IBM MarketScan Commercial and Medicare Claims Databases were examined for patients with CVI-LED. Patient demographics and the use of lymphedema-specific therapy before and after venous intervention were collected. RESULTS: Of 85,601 LED patients identified, 8,406 also had a diagnosis of CVI. In the CVI-LED group, 1051 underwent endovenous ablation or venous stent placement. The use of lymphedema-specific therapy before and after venous intervention was 52% and 39%, respectively (p < .05). The mean time of initiation of LED-specific therapy following venous intervention was 265 days after ablation and 347 days after stent placement. CONCLUSION: Treating venous hypertension improves certain venous-related signs and symptoms of CVI. However, a significant proportion of patients have persistent edema which may reflect underlying, sub-optimally treated LED.
Asunto(s)
Linfedema , Insuficiencia Venosa , Humanos , Insuficiencia Venosa/terapia , Insuficiencia Venosa/epidemiología , Femenino , Masculino , Persona de Mediana Edad , Anciano , Prevalencia , Linfedema/economía , Linfedema/terapia , Linfedema/epidemiología , Enfermedad Crónica , Adulto , Stents/economía , Estados Unidos/epidemiología , Estudios Retrospectivos , Anciano de 80 o más AñosRESUMEN
Introduction: We presented the key findings from Singapore's Changi General Hospital Breast Centre's lymphedema surveillance strategy that used patients' reported symptoms, standard arm circumference measurements and clinical assessment in the diagnosis of breast cancer-related lymphedema (BCRL). Our secondary aim was to highlight and discuss important elements of a surveillance strategy that can be implemented to track this outcome measure of breast cancer treatment for future research. Method: We conducted a cross-sectional study of 511 breast cancer patients to assess the prevalence of BCRL and its associated risk factors. We defined BCRL prevalence rates based on patients' self-reporting, objective arm circumference measure-ments and clinical diagnosis based on International Society of Lymphology (ISL) staging. Results: The median follow-up of patients was 88.8 months. The cumulative prevalence rate in the cohort was 30.9%. The cohort of BCRL patients were older (58.4 versus [vs] 54.9 years), had higher mean Body Mass Index (27.7 vs 25.2), higher proportion of mastectomy (77% vs 64.3%), axillary clearance, less likely breast reconstruction, higher-grade tumour, more lymph nodes excised, more advanced nodal disease, and had undergone adjuvant chemotherapy. However, clinically apparent BCRL was only 6.5% (33 out of 511 patients). The proportion of clinically significant BCRL in patients undergoing sentinel lymph node biopsy (SLNB) or axillary sampling was 1.7% compared to 9.9% in patients who had undergone axillary clearance. Majority of the BCRL were subclinical or mild in severity. Conclusion: Our study showed that our rates of BCRL were comparable to international rates and highlighted similar patient profiles who were at risk of developing the disease. Having a comprehensive lymphedema surveillance strategy is paramount in paving the way for future studies.
Asunto(s)
Linfedema del Cáncer de Mama , Humanos , Femenino , Persona de Mediana Edad , Prevalencia , Estudios Transversales , Factores de Riesgo , Singapur/epidemiología , Linfedema del Cáncer de Mama/epidemiología , Linfedema del Cáncer de Mama/diagnóstico , Linfedema del Cáncer de Mama/etiología , Mastectomía/efectos adversos , Anciano , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/epidemiología , Brazo , Adulto , Índice de Masa Corporal , Escisión del Ganglio Linfático/efectos adversos , Estadificación de Neoplasias , Linfedema/epidemiología , Linfedema/etiología , Linfedema/diagnóstico , Autoinforme , Vigilancia de la Población/métodosRESUMEN
PURPOSE: Natural language understanding (NLU) may be particularly well equipped for enhanced data capture from the electronic health record given its examination of both content-driven and context-driven extraction. METHODS: We developed and applied a NLU model to examine rates of pathological node positivity (pN+) and rates of lymphedema to determine whether omission of routine axillary staging could be extended to younger patients with estrogen receptor-positive (ER+)/cN0 disease. RESULTS: We found that rates of pN+ and arm lymphedema were similar between patients age 55-69 years and ≥70 years, with rates of lymphedema exceeding rates of pN+ for clinical stage T1c and smaller disease. CONCLUSION: Data from our NLU model suggest that omission of sentinel lymph node biopsy might be extended beyond Choosing Wisely recommendations, limited to those older than 70 years and to all postmenopausal women with early-stage ER+/cN0 disease. These data support the recently reported SOUND trial results and provide additional granularity to facilitate surgical de-escalation.
Asunto(s)
Axila , Neoplasias de la Mama , Procesamiento de Lenguaje Natural , Estadificación de Neoplasias , Biopsia del Ganglio Linfático Centinela , Humanos , Femenino , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Persona de Mediana Edad , Anciano , Biopsia del Ganglio Linfático Centinela/métodos , Registros Electrónicos de Salud , Linfedema/etiología , Linfedema/epidemiología , Metástasis Linfática , Ganglios Linfáticos/patología , Ganglios Linfáticos/cirugíaRESUMEN
Background: Breast cancer-related lymphedema (BCRL) is the most prevalent comorbidity that occurs following breast cancer treatments and has negative impact on the patients' quality of life (QoL). The Lymphedema Functioning, Disability, and Health Questionnaire for Upper Limb Lymphedema (Lymph-ICF-UL) is a valid and reliable instrument in assessing the QoL of patients with BCRL. However, the Bahasa Malaysia (BM) version is not available yet. This study aimed to translate the Lymph-ICF-UL into BM and to evaluate its validity and reliability. Methods and Results: A forward-backward translation was performed based on Sousa's guideline, and then, the face, content, construct validity, internal consistency, and test-retest reliability were tested. Face validity was assessed by five patients, and content validity was evaluated by six experts. Then, construct validity and internal validity were assessed in 107 patients. Finally, test-retest reliability was analyzed in 21 patients. Two items were eliminated following suggestions from the patients and experts. All patients found the scoring system and items clear and relevant. The results showed sufficient content validity index and modified kappa statistics value. Confirmatory factor analysis showed acceptable fit indices. Cronbach's alpha values ranged from 0.67 to 0.95, intraclass correlation coefficient ranged from 0.88 to 0.99, standard error measurement was 2.29-6.15, and the Bland-Altman plot showed an agreement between two test occasions. Conclusion: These results suggested that the Lymph-ICF-UL BM has good validity and reliability in evaluating the QoL of patients with BCRL in Malaysia.
Asunto(s)
Linfedema del Cáncer de Mama , Psicometría , Calidad de Vida , Extremidad Superior , Humanos , Femenino , Persona de Mediana Edad , Malasia/epidemiología , Encuestas y Cuestionarios , Reproducibilidad de los Resultados , Linfedema del Cáncer de Mama/diagnóstico , Linfedema del Cáncer de Mama/epidemiología , Linfedema del Cáncer de Mama/psicología , Linfedema del Cáncer de Mama/etiología , Extremidad Superior/fisiopatología , Adulto , Anciano , Linfedema/etiología , Linfedema/diagnóstico , Linfedema/epidemiología , Linfedema/psicología , Evaluación de la Discapacidad , Neoplasias de la Mama/complicaciones , TraducciónRESUMEN
PURPOSE: To clarify how body mass index (BMI) affects the development and temporal trend of breast cancer-related lymphedema (BCRL). METHODS: This is a prospective study in which patients with operable breast cancer were registered in a single institute between November 2009 and July 2010. The incidence of lymphedema at 1, 3, and 5 years after surgery was assessed according to BMI, and the trend of newly developed BCRL was examined. Obesity was defined as BMI ≥25 in accordance with the Japan Society for the Study of Obesity. RESULTS: A total of 368 patients were included in this study. The multivariate analysis of the whole population showed that high BMI, axillary dissection, and radiotherapy remained as risk factors for BCRL. Patients with high BMI showed a significantly higher incidence of new lymphedema than those with low BMI at 1 year (p < 00.001) regardless of axillary procedures (39.1 % vs 16.3 % for axillary dissection; 15.6 % vs 1.5 % for sentinel lymph node biopsy) but not at 3 and 5 years. Once BCRL developed, patients with high BMI showed slow recovery and 50.0 % of the patients retained edema at 5 years while patients with low BMI showed rapid recovery and 26.7 % retained after 3 years (p = 0.04). CONCLUSION: The preoperative BMI affected the incidence and temporal trend of BCRL regardless of axillary procedures or radiotherapy. Patients with high BMI should be given appropriate information about BCRL before surgery with careful follow-up for BCRL after treatment.
Asunto(s)
Axila , Índice de Masa Corporal , Neoplasias de la Mama , Escisión del Ganglio Linfático , Humanos , Femenino , Persona de Mediana Edad , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/complicaciones , Estudios Prospectivos , Anciano , Incidencia , Factores de Riesgo , Adulto , Linfedema del Cáncer de Mama/epidemiología , Linfedema del Cáncer de Mama/etiología , Biopsia del Ganglio Linfático Centinela , Obesidad/complicaciones , Factores de Tiempo , Linfedema/etiología , Linfedema/epidemiología , Mastectomía , Japón/epidemiologíaRESUMEN
INTRODUCTION: Sri Lanka implemented the National Programme for Elimination of Lymphatic Filariasis (NPELF) in its endemic regions in 2002. Five annual rounds of mass drug administration using the two-drug combination diethylcarbamazine (DEC) and albendazole led to sustained reductions in infection rates below threshold levels. In 2016, WHO validated that Sri Lanka eliminated lymphatic filariasis as a public health problem. OBJECTIVE: To explore the impact of the NPELF on lymphatic filariasis morbidity in Sri Lanka. METHODS: Passive Case Detection (PCD) data maintained in filaria clinic registries from 2006-2022 for lymphoedema and hospital admission data for managing hydroceles/spermatoceles from 2007-2022 were analyzed. The morbidity status in 2022 and trends in overall and district-wise PCD rates were assessed. Poisson log-linear models were used to assess the trends in PCD for endemic regions, including district-wise trends and hospital admissions for the management of hydroceles/spermatoceles. RESULTS: In 2022, there were 566 new lymphoedema case visits. The mean (SD) age was 53.9 (16.0) years. The staging was done for 94% of cases, of which 79% were in the early stages (57.3% and 21.4% in stages two and one, respectively). Western Province had the highest caseload (52%), followed by the Southern (32%) and Northwestern (16%) Provinces, respectively. The reported lymphoedema PCD rate in 2022 was 0.61 per 10,000 endemic population. The overall PCD rate showed a decline of 7.6% (95%CI: 4.9% - 10.3%) per year (P < 0.0001) from 2007 to 2022. A steady decline was observed in Colombo, Gampaha and Kurunegala districts, while Kalutara remained static and other districts showed a decline in recent years. Further, admissions for inpatient management of hydroceles/spermatoceles showed a declining trend after 2015. CONCLUSIONS: The PCD rates of lymphoedema and hydroceles/spermatoceles showed a declining trend in Sri Lanka after the implementation of the NPELF.
Asunto(s)
Dietilcarbamazina , Filariasis Linfática , Filaricidas , Filariasis Linfática/epidemiología , Filariasis Linfática/prevención & control , Filariasis Linfática/tratamiento farmacológico , Humanos , Sri Lanka/epidemiología , Masculino , Estudios Retrospectivos , Femenino , Dietilcarbamazina/uso terapéutico , Dietilcarbamazina/administración & dosificación , Adulto , Persona de Mediana Edad , Filaricidas/uso terapéutico , Albendazol/uso terapéutico , Albendazol/administración & dosificación , Salud Pública , Anciano , Hidrocele Testicular/epidemiología , Erradicación de la Enfermedad/métodos , Adolescente , Adulto Joven , Administración Masiva de Medicamentos , Linfedema/epidemiología , Morbilidad/tendencias , Niño , Programas Nacionales de SaludRESUMEN
The generalizability of findings from Clinical Trials (CTs) investigating lymphedema treatment modalities requires an accurate representation of the target population. This study aims to evaluate racial and ethnic reporting and representation in lymphedema CTs. A comprehensive systematic literature search was conducted during May 2023 using multiple databases, following the PRISMA guidelines. All CTs published from 2018 to 2023 were included. A total of 84 articles were included in this review, from which 6,546 participants were included in the analysis. Seventy-four (88.1%) articles addressed secondary lymphedema, of which 60 (81.1%) were related to breast cancer. Only 12 (13%) of CTs reported at some extend race or ethnicity. Of these, five (41.6%) reported race and two (16.6%) reported ethnicity according to FDA guidelines. White race had the highest pooled prevalence (80%; 95% CI 72-86%; I2=90%), followed by Black (7%; 95% CI 2- 15%; I2= 94.3%) and Asian (4%; 95% CI 1-8%; I2= 89.9%). In studies reporting ethnicity, participants were predominantly non-Hispanic (92.1%; 95% CI 90 - 94%). There is an underreporting and underrepresentation of racial and ethnic minorities among lymphedema CTs, limiting their generalizability. It is imperative to future development of strategies to enhance diversity in the study sample.
Asunto(s)
Ensayos Clínicos como Asunto , Minorías Étnicas y Raciales , Linfedema , Humanos , Linfedema/terapia , Linfedema/etnología , Linfedema/epidemiología , Minorías Étnicas y Raciales/estadística & datos numéricos , Etnicidad/estadística & datos numéricos , FemeninoRESUMEN
BACKGROUND: This study aimed to determine the key mental health indicators affecting people affected by lymphatic filariasis (LF) lymphoedema by assessing the prevalence of depressive symptoms and quality of life (QOL), identifying associated sociodemographic and clinical risk factors, and evaluating the impact of an enhanced self-care intervention for lymphoedema management. METHODS: A prospective cohort study of adults with filarial lymphoedema from two regions of Malawi was conducted over six months in 2021. Depressive symptoms and QOL were assessed using Patient Health Questionnaire (PHQ-9) and LF Specific QOL Questionnaire, respectively, at baseline (pre-intervention), 3- and 6-months (postintervention). Beta regression analysis identified risk factors, and assessed the impact of the intervention. RESULTS: Three hundred eleven affected individuals were surveyed with 23% (95% CI 18%-29%) reporting mild/moderate depressive symptoms and 31% (95% CI 26%-37%) reporting moderately low/low QOL. Higher depressive symptom scores were associated with high frequency of acute filarial attack episodes. Individuals with higher depressive symptoms (Adjusted Odds Ratios (AOR) 0.93, 95% CI 0.93-0.93) and lower QOL (AOR 0.98, 0.98-0.98) showed greatest improvement in mental health indicators over 3-months but was not sustained to the same level at 6-months. CONCLUSIONS: Sustained morbidity management and psychological support is recommended for affected persons to ensure long-term positive mental health and clinical outcomes. CONTEXTE: Cette étude vise à déterminer les principaux indicateurs de santé mentale affectant les personnes atteintes de lymphÅdème dû à la filariose lymphatique (FL) en évaluant la prévalence des symptômes dépressifs et la qualité de vie (QV), en identifiant les facteurs de risque sociodémographiques et cliniques associés, et en évaluant l'impact d'une intervention améliorée d'autosoins pour la gestion du lymphÅdème. MÉTHODES: Une étude de cohorte prospective d'adultes atteints de lymphoedème filaire dans deux régions du Malawi a été menée pendant six mois en 2021. Les symptômes dépressifs et la qualité de vie ont été évalués à l'aide du questionnaire sur la santé des patients (PHQ-9) et du questionnaire sur la qualité de vie spécifique au lymphÅdème, respectivement, au début de l'étude (avant l'intervention), et à 3 puis 6 mois après l'intervention. Une analyse de régression beta a permis d'identifier les facteurs de risque et d'évaluer l'impact de l'intervention. RÉSULTATS: Trois cent onze personnes affectées ont été interrogées, dont 23% (95% CI 18%-29%) ont déclaré des symptômes dépressifs légers/modérés et 31% (95% CI 26%-37%) ont déclaré une qualité de vie modérément faible/faible. Des scores élevés de symptômes dépressifs ont été associés à une fréquence élevée d'épisodes de crises filariennes aiguës. Les personnes présentant des symptômes dépressifs plus élevés (rapport de cotes ajusté (RCA) 0.93, IC à 95 % 0.93-0.93) et une qualité de vie plus faible (RCA 0.98, 0.98-0.98) ont montré la plus grande amélioration des indicateurs de santé mentale au cours des trois mois, mais cette amélioration ne s'est pas maintenue au même niveau au cours des six mois suivants. CONCLUSION: Gestion de la morbidité et soutien psychologique sont des éléments clés pour garantir une santé mentale et des résultats cliniques satisfaisants de personnes atteintes sur le long terme. ANTECEDENTES: Este estudio tuvo como objetivo determinar los indicadores clave de salud mental que afectan a las personas afectadas por linfedema por filariasis linfática (FL) mediante la evaluación de la prevalencia de síntomas depresivos y calidad de vida (CdV), la identificación de factores de riesgo sociodemográficos y clínicos asociados, y la evaluación del impacto de una intervención de autocuidado mejorada para el manejo del linfedema. MÉTODOS: Se realizó un estudio prospectivo de cohortes de adultos con linfedema filarial de dos regiones de Malawi durante seis meses en 2021. Los síntomas depresivos y la calidad de vida se evaluaron mediante el Cuestionario de Salud del Paciente (PHQ-9) y el Cuestionario de Calidad de Vida específico para el LF Cuestionario, respectivamente, al inicio (preintervención) y a los 3 y 6 meses (posintervención). El análisis de regresión beta identificó los factores de riesgo y evaluó el impacto de la intervención. RESULTADOS: Se encuestó a 311 afectados, de los cuales el 23% (IC 95%, 18%-29%) presentaba síntomas depresivos leves/moderados y el 31% (IC 95%, 26%-37%) una CdV moderadamente baja/baja CdV. Las puntuaciones más altas de síntomas depresivos se asociaron con una alta frecuencia de episodios de ataques agudos de filarias. Los individuos con mayores síntomas depresivos (Odds Ratios Ajustados [ORA] 0.93; IC 95%: 0.93-0.93) y menor CdV (ORA 0.98; 0.98-0.98) mostraron la mayor mejoría en los indicadores de salud mental a los 3 meses, pero no se mantuvo al mismo nivel a los 6 meses. CONCLUSIONES: Se recomienda el manejo sostenido de la morbilidad y el apoyo psicológico a las personas afectadas para garantizar resultados clínicos y de salud mental positivos a largo plazo.
Asunto(s)
Linfedema , Calidad de Vida , Adulto , Humanos , Estudios Prospectivos , Salud Mental , Autocuidado , Prevalencia , Malaui/epidemiología , Linfedema/epidemiología , Linfedema/terapiaRESUMEN
INTRODUÇÃO: Mulheres com câncer do colo do útero convivem com importantes complicações oriundas do tratamento, dentre elas, o linfedema em membros inferiores. Não é de nosso conhecimento estudo de revisão sistemática sobre incidência e fatores associados ao linfedema pós tratamento do câncer do colo do útero, o que dificulta as estratégias de prevenção. OBJETIVO: Realizar uma revisão sistemática da literatura de estudos de incidência e prevalência do linfedema, e fatores associados a esse desfecho, após tratamento para o câncer do colo do útero. METODOLOGIA: Foi realizada revisão sistemática da literatura, segundo as orientações do PRISMA. Os estudos elegíveis foram identificados por meio das bases de dados: Medline (via PubMed), LILACS, Scopus e Web of Science. Para a busca, utilizou-se descritores, palavras-chaves e sinônimos para: câncer do colo do útero, linfedema e os desfechos de interesse (incidência, prevalência, frequência, ocorrência, morbidade, fatores de risco e prognóstico). Foram incluídos estudos transversais, de coorte retrospectiva ou prospectiva, ou de caso-controle, publicados nos idiomas inglês, português ou espanhol, com dados de frequência ou fatores de risco para o linfedema pós câncer do colo do útero. Os dados foram extraídos e apresentados em tabelas. RESULTADOS: Quinze estudos foram incluídos na revisão. A incidência de linfedema variou de 0 a 69%. A discrepância pode ser atribuída a subnotificação, abordagem de tratamentos diferentes, inclusão de terapia adjuvante, momento e método de avaliação do linfedema e comorbidades. Os fatores de risco para linfedema incluíram radioterapia adjuvante, retirada de linfonodos ilíacos circunflexos, fechamento de retroperitônio, procedimento cirúrgico aberto, celulite, linfocisto pós-cirurgia, IMC ≥ 25 kg/m², realização de linfadenectomia pélvica e para-aórtica. CONCLUSÃO: A frequência de linfedema após o tratamento para câncer do colo do útero é extremamente variável. Os diferentes delineamentos e metodologia empregados pelos autores tornam difícil à comparação entre eles. Não existe um consenso sobre o melhor método empregado no diagnóstico do linfedema e os fatores de risco estão principalmente associados ao tratamento oncológico e a obesidade.
INTRODUCTION: Women with uterine cervical neoplasms coexist with important complications from the treatment, including lymphedema in the lower limbs. We don't know about a systematic review of the incidence and factors associated with lymphedema after treatment of the uterine cervical neoplasms, which hampers prevention strategies. MAIN PURPOSE: Realize a systematic review of the literature of studies of incidence and prevalence of lymphedema, and factors associated with this outcome, after treatment for uterine cervical neoplasms METHOD: A systematic review of the literature was performed according to the PRISMA guidelines. Eligible studies were identified using: Medline (via PubMed), LILACS, Scopus and Web of Science. For the search, we used descriptors, keywords and synonyms for: uterine cervical neoplasms, lymphedema and outcomes of interest (incidence, prevalence, frequency, occurrence, morbidity, risk factors and prognosis). We included cross-sectional, retrospective or prospective, or case-control studies published in the English, Portuguese or Spanish languages, with incidence, or risk factors for lymphedema after cervical cancer. Data were extracted and presented in tables. RESULTS: Fifteen studies were included in the review. The incidence of lymphedema ranged from 0 to 69%. The discrepancy may be attributed to underreporting, approach to different treatments, inclusion of adjuvant therapy, timing and method of lymphedema evaluation, and comorbidities. The risk factors reported included adjuvant radiotherapy, removal of circumflex iliac lymph nodes, retroperitoneal closure, open surgical procedure, cellulitis, lymphocyst formation, BMI ≥ 25 kg / m², pelvic and para-aortic lymphadenectomy. CONCLUSION: The frequency of lymphedema following treatment for uterine cervical neoplasms is extremely variable. The different designs and methodology employed by the authors make it difficult to compare them. There is no consensus on the best method used in the diagnosis of lymphedema and the risk factors are mainly associated with cancer treatment and obesity.
Asunto(s)
Humanos , Femenino , Neoplasias del Cuello Uterino , Linfedema/epidemiología , Revisión SistemáticaRESUMEN
No Brasil, a incidência do linfedema é pouco conhecida e poucas são as documentações científicas reportando a associação do linfedema com os fatores sociais e econômicos na nossa região. O objetivo do estudo foi analisar o impacto dos marcadores socioeconômicos na gravidade do linfedema das extremidades inferiores conforme a classificação de Mowlem, na região metropolitana de Salvador (BA). Dos 324 pacientes estudados, 200 (62 por cento) eram do gênero feminino. A idade variou entre 14 e 69 anos, com mediana de 48 anos. Analisando comparativamente as variáveis: gravidade do linfedema versus grau de escolaridade e gravidade versus renda familiar, observou-se que 93,8 por cento dos pacientes classificados como Mowlem III estavam incluídos no grupo dos pacientes sem escolaridade e/ou com renda familiar de até três salários-mínimos. Não houve registro de doença avançada em pacientes com renda familiar acima de sete salários-mínimos e/ou com terceiro grau completo.
In Brazil, the incidence of lymphedema is poorly known, and there is little scientific documentation reporting the association of lymphedema with the social and economic factors in our region. The objective was to analyze the impact of socioeconomic markers on the severity of lymphedema of the lower extremities according to the classification of Mowlem in the metropolitan region of Salvador (BA), Brazil. Of the 324 patients studied, 200 (62 percent) were female. The age ranged between 14 and 69 years, median 48 years. Comparatively analyzing the varying severity of lymphedema versus education level and severity versus family income, it showed that 93.8 percent of patients classified as Mowlem III were included in the group of patients without education and/or with income up to three minimum wages. There was no record of advanced disease in patients with family incomes greater than seven minimum wages and/or graduate.
Asunto(s)
Humanos , Extremidad Inferior/patología , Linfedema/epidemiología , Índice de Severidad de la Enfermedad , Renta/clasificaciónRESUMEN
OBJECTIVES: This study was designed to compare the prevalence of shoulder-arm morbidity, patient satisfaction with surgery and the quality of life of women submitted to breast-conserving therapy or modified radical mastectomy and immediate breast reconstruction . METHODS: This study was a cross-sectional study of women who underwent breast-conserving therapy (n=44) or modified radical mastectomy and immediate breast reconstruction (n=26). Quality of life was evaluated with the SF-36 Health Survey Questionnaire. RESULTS: No differences were found in the prevalence of lymphedema. The movements that were most commonly affected by these procedures were abduction, flexion and external rotation. When the two groups were compared, however, we only found a statistically significant difference for the prevalence of restricted internal rotation, which occurred in 32 percent of women in the breast-conserving therapy group and 12 percent of those in the modified radical mastectomy and immediate breast reconstruction group (OR: 7.23; p=0.03 following adjustment for potential confounding factors). No difference in quality of life or satisfaction with surgery was found between the two groups. CONCLUSIONS: These data suggest that the type of surgery did not affect the occurrence of lymphedema. Breast-conserving therapy, however, increased the risk of shoulder movement limitation. No differences were found between the two surgical techniques with respect to quality of life or satisfaction with surgery.